Prognostic Factors for Tumor Recurrence after a 12-Year, Single-Center Experience of Liver Transplantations in Patients with Hepatocellular Carcinoma

Table 4

Analysis of factors affecting one-year tumor recurrence rate in patients with HCC.

Variables		One-yr recurrence $n\mathrm{\hspace{0.17em}\hspace{0.17em}}(\%)$	P value
Gender	Female ($n=42$)	10 (24)	.3
	Male ($n=241$)	43 (18)
Age	$\le$ 60 years ($n=184$)	34 (18)	.8
	$>$ 60 years ($n=99$)	19 (19)
AFP $>$ 30 ng/mL at OLT	No ($n=201$)	30 (15)	.01
	Yes ($n=78$)	22 (28)
Viral infection	HCV-positive ($n=152$)	30 (20)	.8
	HBV-positive ($n=70$)	13 (19)
	HCV, HBV-positive ($n=13$)	3 (23)
	HCV, HBV-negative ($n=48$)	7 (15)
Down-staging to MC	No ($n=243$)	46 (19)	.8
	Yes ($n=39$)	7 (18)
Preoperative MC	Fulfilled ($n=224$)	44 (20)	.4
	Not fulfilled ($n=59$)	9 (15)
Preoperative up-to-seven	Fulfilled ($n=267$)	51 (19)	.7
	Not fulfilled ($n=16$)	2 (12)
Pre-OLT treatments	No ($n=53$)	4 (7)	.02
	Yes ($n=222$)	47 (21)
Histological MC	Fulfilled ($n=208$)	36 (17)	.3
	Not fulfilled ($n=75$)	17 (23)
Histological up-to-seven	Fulfilled ($n=249$)	45 (18)	.4
	Not fulfilled ($n=34$)	8 (23)
Grading	G0–G2 ($n=143$)	23 (16)	.2
	G3–G4 ($n=140$)	30 (21)
Microvascular invasion	No ($n=166$)	25 (15)	.06
	Yes ($n=117$)	28 (24)
Macrovascular invasion	No ($n=280$)	52 (19)	.4
	Yes ($n=3$)	1 (33)
Post-OLT m-TOR inhibitors	No ($n=240$)	47 (20)	.3
	Yes ($n=43$)	6 (14)

OLT: orthotopic liver transplantation. HCC: hepatocellular carcinoma. AFP: alpha-fetoprotein. MC: Milan criteria. M-TOR: Mammalian Target Of Rapamycin.